The NH-BMT and Leukemia Programs are committed to publishing in the field of blood and marrow transplantation, Leukemia and hematologic malignancies. The following publications/presentations demonstrate this commitment.
ASH Oral and Poster Presentations: 2025
Collaborative Oral Presentations N=7:
170 Effect of FLT3 maintenance in older FLT3-ITD+ adults undergoing allogeneic HCT. a post hoc analysis of BMT CTN 1506
Sameem Abedin, Victor Baidoo, Aniko Szabo, Richard Jones, Anurag Singh, Mark Litzow, John Wingard, Esperanza Papadopoulos, Alexander Perl, Robert Soiffer, Celalettin Ustun, Masumi Ueda Oshima0, Geoffrey Uy, Edmund Waller, Sumithira Vasu, Melhem Solh, Asmita Mishra, Lori Muffly, Heeje Kim, Matthias Stelljes, Yuho Najima, Masahiro Onozawa, Caroline Chen, Nahla Hasabou, Mathew Rosales, Jason Hill, Stanley Gill, Rishita Nuthethi, Denise King, Adam Mendizabal, Steven Devine, Mary Horowitz, Yi-Bin Chen, Mark Levis, Mehdi Hamadani
256 Phase 2 registrational study of anitocabtagene autoleucel for the treatment of patients with relapsed and/or refractory multiple myeloma: Updated results from iMMagine--1
Krina Patel, Binod Dhakal, Gurbakhash Kaur, Richard Maziarz, Natalie Callander, Adam Sperling, Carolina Schinke, Andrzej Jakubowiak, Noa Biran, Douglas Sborov, Cindy Varga, Larry Anderson, Abhinav Deol, Abraham Kanate, Mehmet Kocoglu, Melhem Solh, Kamalika Banerjee, Krishna Rana, Ana Kostic, Enrique Granados, Carolyn Jackson, Christopher Heery, Ciara Louise Freeman, Tim Welliver, Matthew Frigault
265 A Phase 1 study of KITE-753 or KITE-363 in patients with relapsed/refractory B-cell lymphoma: Initial safety and preliminary efficacy of KITE-753 and updated results of KITE-363
Saurabh Dahiya, Matthew Ulrickson, Jean Yared, Patrick Reagan, Timothy Voorhees , Ran Reshef, Cameron Turtle, Lizamarie Bachier-Rodriguez, Marie José Kersten, Prof. Dr. Max S Topp, Gary Simmons, Robin Sanderson, Loretta Nastoupil, Scott Jung, Enrique Granados, Jinghui Dong, Joshua Winters, Rhine Shen, Justyna Kanska, Myrna Nahas, Sairah Ahmed
267 Azer-cel, an allogeneic (allo) CD19 CAR T, in combination with low-dose interleukin-2 (IL-2) demonstrates clinical activity in patients with large B-cell lymphoma (LBCL) who relapsed after autologous (auto) CAR T
Supriya Gupta, Edmund Waller, Ran Reshef, Vinay Vanguru, Adam Olszewski, Scott Solomon, Joseph Maakaron, Aparna Rava, Sharon Yavrom, John Byon, Bijal Shah
614 Dr. Hong De Sa will moderate Oral session: Prognostic Genetic and Therapeutic Response Factors in Adult and Pediatric B-ALL
455 The MEASURE Genome Atlas: Acute Myeloid Leukemia at diagnosis and complete remission
Kai Yu , Laura Dillon, Jesse Tettero, Gege Gui, Rasha Al-Ali, Michael Grunwald, Elizabeth Krakow, Elizabeth Griffiths, Alexandra Gomez-Arteaga, Rahul Vedula, Melhem Solh, Amandeep Salhotra, Nelli Bejanyan, Lori Muffly, Antonio Jimenez-Jimenez, Michael Drazer, Yi-Bin Chen, Aaron Logan, Reena Jayani-Kosarzycki, Sophia Balderman, James Blachly, Brian Shaffer, Marc Schwartz, Cecilia Yeung, Lawrence Druhan, Vanessa Kennedy, Sandeep Gurbuxani, Melissa Tjota, Max Smith, Farah Sahoo, Dylan Barfield, Jim Guo, James Han, Jason Hu, Heejoon Jo, Vidya Kudlingar, Wilfred Li, Yutong Qiu, Pratheesh Sathyan, Sean Truong, Severine Catreux, Sam Ng, Khai Luong, Yunjiao Zhu, Reem Bahr, Jamie Diemer, Jianqun Kou, Stephanie Bo-Subait, Jackie Bjerke, Steven Devine, Bergetta Dietel, Christina Ferrone, Gabrielle Giammarino, Emily Heying, Emily Kolb, Danielle O'Donnell Vitali, Wael Saber, Stephen Spellman, Brenna Tesch, Jenny Vogel, Stephanie Waldvogel, Syreeta Weatherspoon, Jeffery Auletta, Christopher Hourigan
516 Pre- or post-CAR-T allogeneic hematopoietic cell transplant provides relapse-free survival benefit for R/R Philadelphia negative B-cell acute lymphoblastic leukemia (B-ALL) successfully treated with brexucabtagene autoleucel in the real world
Aaron Logan , Fevzi Yalniz, Amy Zhang, Katharine Miller, Katherine Sutherland, Nikeshan Jeyakumar, Hrishikesh Srinagesh, Michael Grunwald4 Vamsi Kota, Jacob Boccucci, Matthew Ulrickson, Ali AlDarobi6, Joshua Sasine, LaQuisa Hill, Ibrahim Muhsen, Anjali Advani, Ibrahim Aldoss0, Tamer Othman, Karamjeet Sandhu, Ran Reshef, Marlise Luskin, Evan Chen, Chenyu Lin, Ryan Cassaday, Noam Kopmar, Melhem Solh, Catherine Lee, Silvina Odstrcil Bobillo, Stephanie Tsai, Timothy O'Connor, Talal Hilal, Jae Park, Yannis Valtis, Sumithira Vasu, Evandro Bezerra, Eunice Wang, Jessica Leonard, Virginia Tan, Kristen O'Dwyer, Jozal Moore, Ross McCauley, Navneet Majhail, Luke Mountjoy, Aravind Ramakrishnan Shahbaz Malik, Minoo Battiwalla, Paul Shaughnessy, John Mathews, Omer Jamy, Razan Mohty, Muthu Kumaran, Rasmus Hoeg, Wendy Stock, Gregory Roloff, Caspian Oliai, Georgia Lill, Marc Schwartz, Divya Koura, Kaitlyn Dykes, Michael Daunov, Ken Byrd, Veronika Bachanova, Sean Tracy, Punita Grover, Noelle Frey, Matthew Connor, George Yaghmour, Vivian Irizarry Gatell, Clayton Jackson, Olalekan Oluwole, Bhagirathbhai Dholaria, Rawan Faramand, Lori Muffly
1058 Time from AML diagnosis to HCT and pre-HCT FLT3 inhibition impact pre-transplant MRD and benefit from post-HCT gilteritinib
Mark Levis, Mehdi Hamadani, Brent Logan, Richard Jones, Anurag Singh, Mark Litzow, John Wingard, Esperanza Papadopoulos, Alexander Per, Robert Soiffe, Celalettin Ustun, Masumi Ueda Oshima, Geoffrey Uy, Edmund Waller, Sumithira Vasu, Melhem Solh, Asmita Mishra, Lori Muffly, Heeje Kim, Matthias Stelljes, Yuho Najima, Masahiro Onozawa, Kirsty Thomson, Caroline Chen, Nahla Hasabou, Mathew Rosales, Jason Hill, Stanley Gill, Rishita Nuthethi, Denise King, Adam Mendizabal, Steven Devine, Mary Horowitz, Yi-Bin Chen
Program Poster Presentations N=3:
2839 Pre-emptive multidisciplinary approach to overcome the negative impact of high psychosocial risk factor on outcomes after allogeneic hematopoietic cell transplantation
Dawn Speckhart, Krishi Patel, Jennifer Guevara, Joyce Izundu, Xu Zhang, Scott Solomon, H Kent Holland, Asad Bashey, Joseph Maakaron, Lizamarie Bachier-Rodriguez, Melhem Solh. Northside Hospital Cancer Institute, BMT, Leukemia and Immunotherapy Programs, Atlanta, GA, United
4194 Melphalan versus cyclophosphamide combined with fludarabine and low dose total body irradiation (TBI) prior to ptcy-based allogeneic transplantation
Scott Solomon, Lizamarie Bachier-Rodriguez, Joseph Maakaron, Katelin Jackson, Xu Zhang, H. Kent Holland, Asad Bashey, Melhem Solh
6211 Age-related left-digit bias in selection of patients referred for autologous and allogeneic hematopoietic transplantation: An analysis of 877 patients referred to a single center
Asad Bashey, Xu Zhang, H. Kent Holland, Lizamarie Bachier-Rodriguez, Joseph Maakaron, Scott Solomon, Melhem Solh. Northside Hospital Cancer Institute, BMT Cellular Therapy and Acute Leukemia Program, Atlanta, GA
Collaborative Poster Presentations N=13:
667 Firicabtagene autoleucel (firi-cel), a CD22-directed CAR T-cell therapy, for patients with relapsed/refractory large B-cell lymphoma: Results from the phase 2 study (FIRCE-1 Trial)
Matthew Frank, David Qualls, Armin Ghobadi, Jordan Gauthier, Michael Tees, Luke Mountjoy, Joseph McGuirk, Sattva Neelapu, Reem Karmali, Iris Isufi, Brian Hill, Craig Sauter, Catherine Diefenbach, Jay Spiegel, Lizamarie Bachier-Rodriguez, Monalisa Ghosh , Nirav Shah, Rahul Lakhotia, Francisco Hernandez-Ilizaliturri, Anuja Abhyankar, Elise Chong, Matthew Schwede, Krish Patel, Olalekan Oluwole, John Baird, Nathan Denlinger, Farrukh Awan, Michael Jain, John Timmerman, Cesar Sanchez, Muthu Kumaran, Jean Yared, Jon Arnason, Ishan Tatake, Usama Gergis, Peter Riedell, Keith Pratz, Nirali Shah
2391 TSC-101 eliminates recipient hematopoietic cells and demonstrates potential for improved relapse-free survival in patients with AML, ALL, or MDS undergoing allogeneic HCT: Updated results from the Phase 1 (ALLOHA) trial
Monzr M. Al Malki, Yi-Bin Chen, Tania Jain, Alla Keyzner, Melhem Solh, Uday Popat, Michele Donato, Luis Pineiro, Hugo Fernandez, Saar Gill, Anson Snow, Joseph Uberti, Timothy White, Yun Wang, Cuong Nguyen, Chrystal Louis, Shrikanta Chattopadhyay, Michelle Matzko, Ran Reshef
2396 CRS/ICANS Prophylaxis does not Improve Outcomes in adult patients with Relapsed/Refractory B-cell acute lymphoblastic leukemia (B-ALL) treated with brexucabtagene autoleucel
Ross McCauley, Amy Zhang, Vamsi Kota , Jacob Boccucci, Michael Grunwald , Matthew Ulrickson, LaQuisa Hill, Ibrahim Muhsen, Joshua Sasine, Anjali Advani, Ibrahim Aldoss, Karamjeet Sandhu, Ran Reshef, Marlise Luskin, Chenyu Lin, Ryan Cassaday, Noam Kopmar , Melhem Solh, Silvina Odstrcil Bobillo, Stephanie Tsai, Talal Hilal, Bijal Shah, Rawan Faramand, Jae Park, Yannis Valtis, Tamer Othman, Sumithira Vasu, Evandro Bezerra, Jessica Leonard, Virginia Tan, Kristen O'Dwyer, Jozal Moore, Omer Jamy, Razan Mohty, Muthu Kumaran 25 , Rasmus Hoeg 26 , Wendy Stock 27 , Caspian Oliai28 , Georgia Lill28 , Marc Schwartz, Divya Koura, Kaitlyn Dykes, Aaron Logan, Michael Daunov, Ken Byrd, Fevzi Yalniz, Noelle Frey, Matthew Connor, George Yaghmour, Vivian Irizarry Gatell, Clayton Jackson, Olalekan Oluwole, Ali Al-Darobi, Evan Chen, Catherine Lee, Timothy O'Connor, Bhagirathbhai Dholaria, Veronika Bachanova, Sean Tracy, Hrishikesh Srinagesh, Katharine Miller, Katherine Sutherland, Navneet Majhail, Luke Mountjoy, Shahbaz Malik, Aravind Ramakrishnan, Paul Shaughnessy, John Mathews, Eunice Wang, Minoo Battiwalla, Gregory Roloff, Lori Muffly
2400 Trials in progress: Design of a registrational Phase 2 trial (ALLOHA) using an external control arm for TSC-101 for prevention of relapse post allogeneic HCT in patients with ALL, AML, or MDS
Monzr M. Al Malki, Yi-Bin Chen, Tania Jain, Alla Keyzner, Melhem Solh, Uday Popat, Michele Donato, Luis Pineiro, Hugo Fernandez, Saar Gill, Anson Snow, Joseph Uberti, Sameem Abedin, Mahasweta Gooptu, Mathew Angelos, Jeremy Pantin, Kwang Woo Ahn, Ramola Bhandarkar, Shrikanta Chattopadhyay, Samantha Jaglowski, Chrystal Louis, Michelle Matzko, Leavitt Morrison, Waleska Pérez, Eugene Poggio, Ran Reshef
2715 Patient characteristics, toxicity, and response after real world administration of obecabtagene autoleucel and brexucabtagene autoleucel for relapsed acute lymphoblastic leukemia: A rocca analysis
Yannis Valtis, Karamjeet Sandhu, Rawan Faramand, Amy Zhang, Katharine Miller, LaQuisa Hill, Ibrahim Muhsen, Tamer Othman, Marlise Luskin, Evan Chen, Caspian Oliai, Georgia Lill, Ryan Cassaday, Noam Kopmar, Aaron Logan, Matthew Connor, Talal Hilal, Jae Park Melhem Solh, Caitlin Guzowski, Jessica Leonard, Virginia Tan, Nikeshan Jeyakumar, Hrishikesh Srinagesh, Muthu Kumaran, Rasmus Hoeg, Divya Koura, Kaitlyn Dykes, Wendy Stock, Vivian Irizarry Gatell, Clayton Jackson, Olalekan Oluwole, Bhagirathbhai Dholaria, Kristen O'Dwyer, Jozal Moore, Matthew Ulrickson, Ali Al-Darobi, Ken Byrd, Stephanie Tsai, Timothy O'Connor, Eunice Wang, Ross McCauley, Omer Jamy, Razan Mohty, Gregory Roloff, Katherine Sutherland, Ibrahim Aldoss, Bijal Shah , Lori Muffly, Noelle Frey
3365 KMT2Ar, but not other high-risk genetics, adversely impacts outcomes in adult patients with relapsed/refractory (R/R) Philadelphia chromosome negative B-cell acute lymphoblastic leukemia (B-ALL) treated with brexucabtagene autoleucel (Brexu-cel)
Jessica Leonard, Abdullah Ladha, Rawan Faramand, Gregory Roloff, Yannis Valtis , Virginia Tan, Katharine Miller, Amy Zhang , Michael Grunwald, Vamsi Kota, Jacob Boccucci, Matthew Ulrickson, Ali Al-Darobi, LaQuisa Hill, Ibrahim Muhsen, Joshua Sasine, Anjali Advani, Karamjeet Sandhu, Ran Reshef, Marlise Luskin, Evan Chen, Chenyu Lin, Ryan Cassaday, Noam Kopmar, Melhem Solh, Catherine Lee, Silvina Odstrcil Bobillo, Stephanie Tsai, Timothy O'Connor, Talal Hilal, Jae Park, Sumithira Vasu, Evandro Bezerra, Kristen O'Dwyer, Jozal Moore, Eunice Wang, Ross McCauley, Navneet Majhail, Aravind Ramakrishnan, Luke Mountjoy, Shahbaz Malik, Minoo Battiwalla, Paul Shaughnessy, John Mathews, Hrishikesh Srinagesh, Katherine Sutherland, Omer Jamy, Razan Mohty 32 , Muthu Kumaran 33 , Rasmus Hoeg 34 , Caspian Oliai35 , Georgia Lill, Wendy Stock, Marc Schwartz, Tamer Othman, Divya Koura, Kaitlyn Dykes, Aaron Logan, Michael Daunov, Ken Byrd, Fevzi Yalniz, Veronika Bachanova, Sean Tracy, Punita Grover, Matthew Connor, George Yaghmour, Vivian Irizarry Gatell, Clayton Jackson, Olalekan Oluwole, Bhagirathbhai Dholaria, Noelle Frey, Lori Muffly, Bijal Shah, Ibrahim Aldoss
3710 Lisocabtagene maraleucel (liso-cel) versus standard of care (SOC) for second-line relapsed or refractory large B-cell lymphoma (LBCL): First Results from long-term follow-up of TRANSFORM
Manali Kamdar, Scott Solomon, Jon Arnason, Patrick Johnston, Bertram Glass, Veronika Bachanova, Sami Ibrahimi, Stephan Mielke, Pim Mutsaers, Francisco Hernandez-Ilizaliturri, Koji Izutsu, Franck Morschhauser, Matthew Lunning, Vincent Ribrag, Yi Lin, Rashmi Bhatnagar, Sandrine Montheard, Jeremy Abramson
4209 Germline genetic variants and post-HCT cytokine/chemokine milieu may identify those at higher risk of primary graft failure after allogeneic hematopoietic cell transplantation, a blood and marrow transplant clinical trials network (BMT CTN) study
Kirsten Williams, Jennifer Holter-Chakrabarty, Sara Vesely, Marie Gordon,, Ashwin Koppay, Yvonne Suessmuth, Iskra Pusic, John McCarty, Philip McCarthy, Asad Bashey, Gregory Yanik, Michelle Schoettler, Valerie Stewart, Sarita Layton, Stephen Spellman, Wael Saber, Christopher Porter, Lucy Godley
4219 Coronary artery calcification and its effect on cardiac events in patients undergoing allogeneic stem cell transplantation using nonmyeloablative conditioning
Christopher Graham, Roy Kao, Qing Cao, Cameron McDonald-Hyman, Joseph Norton, Punita Grover, Joseph Maakaron, Jeremy Allred, Veronika Bachanova, Jeffrey Miller, Daniel Weisdorf, Mark Juckett
5807 Trial in progress: A phase 1 study to evaluate the safety and preliminary efficacy of arlocabtagene autoleucel (arlo-cel), a GPRC5D-targeted chimeric antigen receptor (CAR) T cell therapy, in combination with mezigdomide (MEZI) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)
Susan Bal, Luciano Costa, Nizar Bahlis, Myo Htut, Omar Nadeem, Krina Patel, Scott Solomon, Jaclyn Davis, Ziyan Guo, Kevin Hsu, Hongxiang Hu, Krishna R. Juluri, Jessica Katz, Timothy Pulham, Safiyyah Ziyad, Sham Mailankody
5865 IL-39/IL-39R signaling drives acute graft-versus-host disease
Denggang Fu, Michael Martens, Michael Hendrix, Allison Pugel, Qiao Cheng, Amin Alousi, Iskra Pusic, George Carrum, Asad Bashey, Stephanie Lee, John Levine, Yongxia Wu, Mehdi Hamadani, Xue-Zhong Yu
6302 Intrathecal chemotherapy for management of immune effector cell-associated neurotoxicity syndrome (ICANS): A multi-center, real-world analysis of clinical outcomes
Adam Kidwell, Karolina Lungova, Aniko Szabo, Emilie Aschenbrenner, Timothy Schieber, Forat Lutfi, Wilder Widman, Austin Quick, Ashley Dunton, Bhagirathbhai Dholaria, Olalekan Oluwole, Rita Ahmad, Seth Maliske, Caitlin Guzowski, Scott Solomon, Melissa Babcook, Nathan Denlinger, Nirav Shah
6381 Treatment selection and functional outcomes in treatment-related acute myeloid leukemia (tAML) and AML with myelodysplasia-related changes (MRC): A multicenter prospective cohort study
Vijaya Bhatt, Christopher Wichman, Joseph Maakaron, Richard Stone, Moataz Ellithi, Michael Haddadin, Lori Maness, Soroush Mortaz-Hedjri, Steven Green, Kah Poh (Melissa) Loh, Sarah Wall, Krishna Gundabolu